Clinical Trial Update: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of NanoLithium NP03 in patients with mild-to-severe Alzheimer's disease has completed. Sponsor: Medesi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NanoLithium NP03 (lithium nanoparticle formulation NP03)

Snippet

Sponsor: Medesis Pharma SA | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED